DIAGNOSTIC_TEST · Unmapped registry intervention
99mTc-pyrophosphate Scintigraphy
Find medicine records ·
Find other trials using this name
Clinical trial
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
NCT05577819
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedPrevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Transthyretin Amyloidosisunresolved
Heart Failureverified · MONDO: heart failure
Amyloidosisverified · MONDO: amyloidosis
Interventions
99mTc-pyrophosphate ScintigraphyDIAGNOSTIC_TEST
Sponsors & collaborators
Massachusetts General Hospitallead sponsor
Akcea Therapeuticscollaborator
Pfizercollaborator
Alnylam Pharmaceuticalscollaborator
Eidos Therapeutics, a BridgeBio companycollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05577819 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.